MapLight Therapeutics Reports Phase 2 Trial Results for Schizophrenia Drug

AI-generated NewsSnap summary based on source reporting.
Published: 2026-07-27
Category: business
Source: SEC.gov
Original source

MapLight Therapeutics, Inc. announced topline results from its Phase 2 ZEPHYR trial for ML-007C-MA, a drug candidate for inpatient adults with schizophrenia experiencing acute psychosis. The company disclosed these findings in a press release and an SEC Form 8-K filing. These results are crucial for the drug's potential development.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai